Illumina is a biotechnology company that develops and markets integrated systems for biological function analysis. These studies, with the support of Illumina's innovative solutions, will lead the way for personalized medicine in the future. The company also conducts disease research, drug development, and molecular test development.
158 Reviews
At this point, the flexible work arrangements are the only nice thing about this company
Pay sucks, company really pushing the kool aid that were still the best of the best when in reality we fumbled the bag hard on having a monopoly in the sequencing space.
The Bargain Genome: Illumina Cuts Price to $200 With New Sequencer Machines The Healthcare Technology Report.
Sioux City Catholic GlobeIllumina, Inc. (NASDAQ:ILMN - Get Rating) - SVB Leerink lowered their Q1 2023 earnings per share (EPS) estimates for Illumina in a research report issued on Wednesday, October 19th. SVB Leerink analyst P. Souda now anticipates that the life sciences company will post earnings of $0.87 per share f
Sioux City Catholic Globe
